Striving for new therapies that make patients' lives better

We have an extensive pipeline of investigational product candidates that are progressing through all stages of human clinical trials. Our product candidates address many serious medical conditions including cancer, eye diseases, inflammatory diseases, pain, cardiovascular diseases and allergic conditions.

Peter Powchik, M.D. Senior Vice President, Clinical Development "We have the enviable ability to add several additional fully human antibodies to the clinical pipeline each year due to the productivity of our discovery and development platforms."

Looking for Information on Investigator Initiated Studies?
http://iisgrants.regeneron.com

VelociGene® Technology

Regeneron scientists have developed novel methods for assigning functions to genes and creating preclinical disease models.

More On Our Technology Platform

Product
Candidate

Category Under Study

Sarilumab (REGN88)
IL-6R Antibody

Rheumatoid arthritis
Dupilumab (REGN668)
IL-4R Antibody
Atopic dermatitis in adults, asthma
REGN2222
RSV Antibody
Respiratory syncytial virus
Fasinumab (REGN475)
NGF Antibody
Pain due to osteoarthritis, chronic lower back pain
Dupilumab (REGN668)
IL-4R Antibody
Atopic dermatitis in children,
nasal polyps, eosinophilic esophagitis

Sarilumab (REGN88)
IL-6R Antibody

Non-infectious uveitis
Trevogrumab (REGN1033)
GDF8 Antibody
Skeletal muscle disorders
REGN2176-3
Rinucumab (PDGFR-beta
Antibody) + Aflibercept
Wet age-related macular degeneration
Evinacumab (REGN1500)
Angptl3 Antibody
Homozygous familial hypercholesteroemia,
severe forms of hyperlipidemia
REGN910-3
Nesvacumab (Ang2 Antibody)
+ Aflibercept
Wet age-related macular degeneration,
diabetic macular edema
REGN2810
PD-1 Antibody
Advanced cutaneous squamous cell carcinoma
REGN1979
CD20/CD3 Antibody
Cancer
REGN1908-1909 Allergic disease

This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.

Close
Form content here please :)